Business
PetLife Pharmaceuticals is Pleased to Showcase its New “Vitalzul™ Information Video” along with a Corporate Update
PetLife Pharmaceuticals is Pleased to Showcase its New “Vitalzul™ Information Video” along with a Corporate Update.
About this update from Petlife Pharmaceuticals Inc
[{"type":"text","content":"\n\n Hancock, MD, Oct. 10, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the \"Company\"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to provide a detailed information video on Vitalzul™.\n PetLife is excited to release its new Vitalzul™, Organic Health for Pets video: https://youtu.be/aaIDk-ufjgk (YouTube version) and https://goo.gl/B9aEGd (Dropbox version) The Vitalzul™ video includes testimonials, veterinarian discussions of the treatment process by Dr. Mitchell, PetLife’s VP of Veterinary Affairs, and a discussion by Dr. Salvagno, CEO of PetLife Pharmaceuticals. The video highlights the urgency in addressing this cancer epidemic in pets and the lack of affordable solutions available in the market today. Vitalzul™ hopes to address this need globally by providing an affordable, natural solution for our companion pets with no known negative side effects. In America alone, an estimated 11,000,000 pet owners chose euthanasia last year over a costly and toxic oncological treatment regiment. The toxicity of conventional drugs like chemotherapy may kill the pet before the cancer. “I am excited to be part of PetLife and Vitalzul™’s product development and testing. The results we are seeing with our patients are fantastic. Now that pre-INAD studies have begun, we are on our way towards FDA/CVM submission” stated Dr Mitchell, PetLife’s VP of Veterinary Affairs. In preparation for the FDA/CVM process, the company has retained the services of InnoVision Therapeutics, a seasoned company, whose principals have decades of success in successfully registering a variety of drugs with the FDA/CVM. They will be navigating the pathway through the FDA/CVM registration process for PetLife’s leading drug Vitalzul™. In addition, Petlife Pharmaceuticals has rebranded the drug and changed the name from Escozine to Vitalzul™. Last week, management completed the restructuring of PetLife’s share structure, with the final step being the removal of the D designation. The designated symbol on the OTCQB is PTLF. Petlife’s 506 Private Placement Memorandum is available only to accredited investors. About PetLife Pharmaceuticals, Inc. PetLife Pharmaceuticals (OTCQB: PTLF) (ht...